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Nitric oxide is an endogenous molecule that play an important role in the regulation of the systemic, 
cardiac and pulmonary circulations. We investigated the frequency of intron 4 VNTR ecNOS gene 
polymorphism in Ivorian and Italian populations. The frequencies of the bb, ab and aa genotypes 
were 0.422, 0.476, and 0.102, respectively, for the Ivorian sample, and 0.683, 0.300, and 0.017, 
respectively, for the Italian sample. The frequencies  of 4b and 4a alleles were 0.660 and 0.340, 
respectively, for the Ivorian group, and 0.833 and 0.167, respectively, for the studied Italian 
population. The genotype frequencies were in Hardy-Weinberg equilibrium in both populations. No 
differences were found in ecNOS genotype and allele frequencies between sexes. The Ivorian 
population showed a significantly higher frequency of the 4a allele with respect to North African 
populations (Tunisia, Algeria and Morocco) and to the African-Brazilian sample. Viceversa, the 
Italian population did not show any significant differentiation with respect to other European 
populations, with exception of the Holland and Turkey samples, confirming the high genetic 
homogeneity of Italy and Europe in the distribution of this polymorphism. In the Ivorian sample the 
4a allele was prevalently found in a heterozygous status. A possible explanation could be that the 
heterozygote individuals produce a sufficient level of NO metabolites, although in lower amount 
with respect to the bb genotypes. As a consequence, the 4a allele is maintained prevalently in a 
heterozygous status and does not provoke an effective selective disadvantage for the carriers.  
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Introduction 
Nitric oxide (NO) is an endogenous highly reactive molecule that play an important role in the 
regulation of vascular smooth muscle cell proliferation and migration, in the endothelial 
permeability, and in the endothelial-leucocyte interaction. Because of these properties, NO has been 
established as being a regulator of the systemic, cardiac and pulmonary circulations [1], with an 
important antithrombotic and antimicrobial role [2, 3]. An impairment of NO production has been 
showed to be related to many diseases, including coronary artery disease [4], ischemic stroke	  [5],	  	  
hypertension [6], renal disease [7], and Alzheimer’s disease [8]. At cellular level, an overproduction 
of NO has been described to be associated to DNA damage, cell cycle arrest, and cellular apoptosis 
[9], whereas reduction in basal NO release may predispose to hypertension, thrombosis, vasospasm 
and atherosclerosis [10].  
NO is synthesized from the amino acid L-arginine by nitric oxide synthase (NOS) [11]. Three 
distinct isoforms of NOS, neuronal NOS (nNOS), inducible NOS (iNOS), and endothelial 
constitutive NOS (ecNOS) have been identified in humans. ecNOS produces the majority of 
circulating NO [12] and, with nNOS, it is constitutively expressed in both airway and vascular 
endothelia. The continuously generated NO serve to maintain basal vascular NO production 
necessary for a good endothelial function and blood flow regulation, particularly coronary flow.  
The ecNOS is encoded by a gene located on chromosome 7q35-q36 (13-15) and composed of 26 
exons that span more than 21 kb of the genome [13]. Several polymorphisms were reported in the 
promotor region, exons, and introns of this gene, and an important one is represented by a 27-base 
pair core consensus VNTR (variable number of tandem repeats) polymorphism in the intron 4 [14]. 
The common wild-type ‘b-allele’ (4b allele) has five tandem 27-bp repeats and has been designated 
as ecNOS4b, while a rare ‘a-allele’ (4a allele) has been detected with only four repeats.  Tsukada et 
al. (1998) [15] reported that ecNOS gene polymorphisms correlate with the circulating NO 
concentrations and individuals with bb and aa genotypes exhibit the highest and the lowest activity, 
respectively. The four repeats of VNTR, influencing the plasma NO levels and ecNOS protein 
expression [12, 15], were reported to be involved in the pathogenesis of several diseases including 
coronary heart disease [4, 16,17], lung disease [18], hypertension [6, 19], atopic asthma [20], and 
early-onset colorectal cancer [21]. 
Published papers about this gene polymorphism refer mostly to case-control studies, and only few 
population genetic studies were published in order to assess the frequency of this polymorphism in 
populations worldwide. The aim of this study was to investigate the genetic variability at ecNOS 
locus in an African population from Ivory Coast and in an European population from Italy, for 
which no data has been published about ecNOS intron 4 VNTR polymorphism. We also compared 
our results with those reported from other control populations sampled worldwide, in particular 
from African and European groups. 
 
Materials and Methods 
Population studied  
The African sampling was performed in Ouangolodougou, a rural village of  20.000 inhabitant 
located on the Northern Ivory Coast. One hundred twenty-eight unrelated individuals (59 males and 
69 females, mean age 31.9±14,5) were analyzed. The Italian sampling was performed in Piedmont, 
a region of Northern Italy. Two hundred and forty individuals (112 males and 128 females, mean 
age 58.36±6.7) were analyzed. All the subjects were healthy volunteers and had received 
information about the study. The study has been approved by the local ethics committee and has 




Peripheral blood samples (5-10 ml venipuncture) were collected in heparinized vacutainers and 
stored at –20°C. To extract DNA we used Chelex solution protocol [22]. To determine the ecNOS 
genotype, a genomic DNA fragment of intron 4 of the ecNOS gene was amplified by PCR, using 
the following primers: forward primer 5′-AGGCCCTATGGTAGTGCCTTT-3′ and the reverse 
primer 5′-TCTCTTAGTGCTGTGGTCAC-3′. PCR reactions were carried out in a total volume of 
25 µl containing 10 ng of DNA (template), with a final concentration of 1X Reaction Buffer, 1.5 
mM of MgCl2, 5% of DMSO, 250 µM of dNTPs, 0.5 µM of each primer, and 1U/sample of Taq 
DNA polymerase (Fischer, U.S.). The reaction profile was: 30 cycles of 94°C for 1 min, 56°C for 1 
min., 72°C for 1 min, with a final extension at 72°C for 10 min. PCR products were separated by 
electrophoresis on a 4% Nusive high resolution agarose gel and visualized by ethidium bromide 
staining. Amplification yielded either a 420 bp (five repeats of the 27-bp sequence) fragment or a 
393 bp (four repeats of the 27-bp sequence) fragment or both (heterozygous genotype).  A 10% of 
the samples were amplified twice for checking the accuracy of the results. Moreover, in order to 
confirm that the amplified products represent genuine ecNOS intron 4 regions, selected PCR 
amplified segments, corresponding to a/a and b/b genotypes, were completely sequenced at both 
strands. 
 
Statistical analysis  
The allele and genotype frequencies were determined using GENEPOP program. Hardy-Weinberg 
equilibrium was evaluated by the Chi-square (χ2) test using a 95% confidence interval. Allele 
frequencies obtained in the studied samples were compared with those reported for other European 
and African populations, through contingency tables analyzed with a  χ2-test. 
 
Results and Discussion 
The frequency distribution of ecNOS 27-bp repeat polymorphism of intron 4 within the study 
groups was presented in Table 1. The frequencies of the bb, ab and aa genotypes were 0.422, 0.476, 
and 0.102, respectively, for the Ivorian sample, and 0.683, 0.300, and 0.017, respectively, for the 
Italian sample. The frequencies  of 4b and 4a alleles were 0.660 and 0.340, respectively, for the 
Ivorian group, and 0.833 and 0.167, respectively, for the studied Italian population.  
The genotype frequencies distribution of this polymorphism was in Hardy-Weinberg equilibrium in 
both populations. Because of existing gender differences in NO production [23, 24], allele and 
genotype frequencies of the ecNOS polymorphisms were analyzed separately in men and women. 
No differences were found in ecNOS genotype and allele frequencies distribution between sexes  
(Table 1). 
The ecNOS intron 4 VNTR polymorphism has been analyzed in several human populations (Table 
2), mostly in order to ascertain its association with several type of diseases. Results showed a 
significant (P<0.001) decreasing gradient of the 4a allele frequency from Africa to Europe, America 
and Asia, probably ascribed to a founder effect due to ancient migrations of geographically distinct 
and isolated groups from Africa to other continents. In addition, being this polymorphism involved 
in the pathogenesis of several diseases, this different distribution pattern of the allele frequencies 
could also be the result of a selective pressure exerted on different populations.  
Our Ivorian sample showed similar allele frequency values with respect to the other Ivorian sample 
genotyped for the same polymorphism, but a significantly (p<0.001) higher frequency of the 4a 
allele with respect to North African populations (Tunisia, Algeria and Morocco) and to the African-
Brazilian sample (Table 2).  
This different distribution pattern among Africans could probably be attributed to the different 
evolutionary histories of the different ethnic groups, in particular of the Northern Africa populations 
with respect to West and South Africa groups.  In Africa, the genetic structure of many otherwise 
genetically “neutral” systems, such as mitochondrial DNA variation, has already been demonstrated 
[25]. Therefore, it is not surprising to discover differences between west and north African 
populations. 
Viceversa, the Italian population, did not show any significant  level of differentiation with respect 
to other European populations previously analysed for the same genetic marker, with exception of 
the Holland and Turkey samples (p<0.001), confirming the high genetic homogeneity of Italy and 
Europe in the distribution of this polymorphism.  
According to many global surveys of genetic markers demonstrating that the African populations 
have consistently greater diversity than other populations [26, 27], our African sample showed an 
high frequency of heterozygous genotypes, indicating an high level of heterozygosity to the studied 
locus. It was found that the four repeats of VNTR influence the plasma NO levels. Indeed, the 4a 
allele of the ecNOS gene was related to low NO metabolite levels, and subjects homozygous for the 
4a allele exhibit about 20% lower levels of NO metabolites than subjects with the b/b genotype 
[15]. Among Ivorians, the 4a allele was found prevalently in a heterozygous status. A possible 
explanation could be that the heterozygote individuals produce a sufficient level of NO metabolites, 
although in minor amount with respect to the bb genotypes. As a consequence, the 4a allele is 
maintained prevalently in a heterozygous status and does not provoke an effective selective 
disadvantage for the carriers.  
In conclusion, we reported on novel frequency data as regards ecNOS intron 4 VNTR 
polymorphism in Ivorian and European populations, thereby extending previous observations 
obtained from other worldwide populations. Considering the implication of this polymorphism in 
many diseases and the scarcity of data about the prevalence of these diseases principally among 
African populations, further studies are needed to address the impact of selective constraints on the 
variability associated to this polymorphism in different populations and ethnic groups.  	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Table 1 – Allele and Genotype Frequencies of intron 4 VNTR ecNOS gene polymorphism in the 
studied populations  
Population N Genotype (frequency) 
        bb                  ba                  aa 
Allele (frequency) 
       b                    a 
Ivory Coast 128 54 (0.422)     61 (0.476)     13 (0.102) 169 (0.660)     87 (0.340) 
Male 58 28 (0.483)     22 (0.379)       8 (0.138) 78 (0.672)     38 (0.328) 
Female 70 26 (0.372)     39 (0.557)       5 (0.071) 91 (0.650)     49 (0.350) 
    
Italy 240 164 (0.683)     72 (0.300)       4 (0.017) 400 (0.833)      80 (0.167) 
Male 112 78 (0.696) 34 (0.304)       0 (0.000) 190 (0.848)      34 (0.152) 
Female 128 86 (0.672) 38 (0.297)       4 (0.031) 210 (0.820)      46 (0.180) 
 
 
Table 2 – Allele and Genotype Frequencies of intron 4 VNTR ecNOS gene polymorphism in the 
studied and other populations worldwide distributed 
Population N Allele (frequency) 
      b                            a 
References 
Africa    
Ivory Coast 128   169 (0.660)       87 (0.340)* Present Study 
Tunisia 250   431 (0.862)     69 (0.138)* [28] 
Algeria 122   202 (0.828)       42 (0.172)* [29] 
Morocco  (Berber) 117   190 (0.812)       44 (0.188)* [30] 
Ivory Coast 109   138 (0.633)       80 (0.367) [30] 
African-Brazilians 121   194 (0.802)       48 (0.198)* [31] 
African-Americans 58     81 (0.698)       35 (0.302) [32] 
Pooled Africa  905   1405 (0.776)   405 (0.224)a,b,c  
    
Europe    
Italy 240   400 (0.833)     80 (0.167)& Present Study 
Italy (Sardinia) 189   336 (0.889)       42 (0.111) [30] 
Spain 499   859 (0.861)     139 (0.139) [30, 33] 
Holland 466   839 (0.900)     93 (0.100)& [34] 
Turkey 488   873 (0.894)   103 (0.106)& [35, 36, 47] 
Polish 321   553 (0.861)     89 (0.139) [38] 
Germany 941 1572 (0.835)   310 (0.165)  [39, 40] 
Austria 133   228 (0.857)     38 (0.143) [41] 
Czech Republic 316   517 (0.818)   115 (0.182) [42] 
Finland 110   184 (0.836)     36 (0.164) [43] 
Scotland 300   526 (0.877)     74 (0.123) [44] 
Greece 295   492 (0.834)     98 (0.166) [45] 
Greece, Crete 160   279 (0.872)       41 (0.128) [46] 
Pooled Europe 4458 7658 (0.859)  1258 (0.141)a,d  
    
America    
Amerindians 170   326 (0.959)     14 (0.041) [47] 
Colombia 859 1474 (0.858)   244 (0.142) [48] 
Pooled America 1029 1800 (0.875)   258 (0.125)b  
    
Asia    
South Korea 224   412 (0.920)     36 (0.080) [49, 50] 
China  216   392 (0.907)     40 (0.093)  [51, 52]  
India  769 1274 (0.828)    264 (0.172)  [53, 54, 55] 
Japan 1329 2409 (0.906)    249 (0.094)  [17, 56, 57, 58, 59] 
Pooled Asia 2538 4487 (0.884)  589 (0.116)c,d  
* = significantly different (P<0.001) with respect to our studied Ivorian sample 
& = significantly different (P<0.001) with respect to our studied Italian sample 
 a,b,c,d = P<0.001 
